ResultsIQ

ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q2 FY27 earnings call summary

NSE: SUDEEPPHRM · BSE: 544619

Earnings call of 29 Oct 2026, summarised by AI from the filing.

Specialty Ingredients expected to return to positive year-on-year growth in Q3 and Q4, assuming no Fortified Rice restart.

Key takeaways

  1. Guidance Specialty Ingredients expected to return to positive year-on-year growth in Q3 and Q4, assuming no Fortified Rice restart.
  2. PFN growth PFN revenue grew 57% to ₹142 cr on phosphates and magnesium bisglycinate volumes, with segment EBITDA margin about 41%.
  3. Freight cost Elevated sea freight added about ₹8 cr to selling and distribution spend, absorbed without passing it to customers.

Original filing on BSE

Sudeep Pharma Limited Q2 FY27 results

As filed: Revenue ₹197 cr (+21% year on year), EBITDA ₹73.2 cr (+31% year on year), PAT ₹51.8 cr (+10% year on year), EBITDA margin 37.2% (+288 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +48.3% in 30 days (Nifty 500: −1.8%).
  • Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.